Beyond immortality: Epstein–Barr virus and the intricate dance of programmed cell death in cancer development

IF 2.4 Q3 Medicine Cancer treatment and research communications Pub Date : 2024-01-01 Epub Date: 2025-02-05 DOI:10.1016/j.ctarc.2025.100880
Arezoo Esmaeili , Prankur Awasthi , Samira Tabaee
{"title":"Beyond immortality: Epstein–Barr virus and the intricate dance of programmed cell death in cancer development","authors":"Arezoo Esmaeili ,&nbsp;Prankur Awasthi ,&nbsp;Samira Tabaee","doi":"10.1016/j.ctarc.2025.100880","DOIUrl":null,"url":null,"abstract":"<div><div>This comprehensive review delves into the intricate role of programmed cell death in Epstein–Barr virus (EBV)-associated malignancies, focusing on the sophisticated interplay between viral mechanisms and the host's immune response. The central objective is to unravel how EBV exerts control over cell death pathways such as apoptosis, ferroptosis, and autophagy, thereby fostering its persistence and oncogenic potential. By dissecting these mechanisms, the review seeks to identify therapeutic strategies that could disrupt EBV's manipulation of these pathways, enhancing immune recognition and opening new avenues for targeted treatment. A deeper understanding of the molecular underpinnings of EBV's influence on cell death not only enriches the field of viral oncology but also pinpoints targets for drug development. Furthermore, the insights gleaned from this review could catalyze the design of vaccines aimed at preventing EBV infection or curtailing its oncogenic impact. Innovatively, the review synthesizes recent discoveries on the multifaceted roles of non-coding RNAs and cellular signaling pathways in modulating cell death within the context of EBV infection. By consolidating current knowledge and identifying areas where understanding is lacking, it lays the groundwork for future research that could lead to significant advancements in vaccine development and therapeutic interventions for EBV-related cancers. This review underscores the critical necessity for ongoing investigation into the complex interplay between EBV and host cell death mechanisms, with the ultimate goal of enhancing patient outcomes in EBV-associated diseases.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100880"},"PeriodicalIF":2.4000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer treatment and research communications","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2468294225000188","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/5 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

This comprehensive review delves into the intricate role of programmed cell death in Epstein–Barr virus (EBV)-associated malignancies, focusing on the sophisticated interplay between viral mechanisms and the host's immune response. The central objective is to unravel how EBV exerts control over cell death pathways such as apoptosis, ferroptosis, and autophagy, thereby fostering its persistence and oncogenic potential. By dissecting these mechanisms, the review seeks to identify therapeutic strategies that could disrupt EBV's manipulation of these pathways, enhancing immune recognition and opening new avenues for targeted treatment. A deeper understanding of the molecular underpinnings of EBV's influence on cell death not only enriches the field of viral oncology but also pinpoints targets for drug development. Furthermore, the insights gleaned from this review could catalyze the design of vaccines aimed at preventing EBV infection or curtailing its oncogenic impact. Innovatively, the review synthesizes recent discoveries on the multifaceted roles of non-coding RNAs and cellular signaling pathways in modulating cell death within the context of EBV infection. By consolidating current knowledge and identifying areas where understanding is lacking, it lays the groundwork for future research that could lead to significant advancements in vaccine development and therapeutic interventions for EBV-related cancers. This review underscores the critical necessity for ongoing investigation into the complex interplay between EBV and host cell death mechanisms, with the ultimate goal of enhancing patient outcomes in EBV-associated diseases.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
超越不朽:爱泼斯坦-巴尔病毒和癌症发展过程中细胞程序性死亡的复杂舞蹈
本综述深入研究了程序性细胞死亡在eb病毒相关恶性肿瘤中的复杂作用,重点研究了病毒机制与宿主免疫反应之间的复杂相互作用。中心目标是揭示EBV如何控制细胞死亡途径,如凋亡、铁凋亡和自噬,从而促进其持久性和致癌潜力。通过剖析这些机制,本综述旨在确定可能破坏EBV对这些途径的操纵的治疗策略,增强免疫识别并为靶向治疗开辟新的途径。更深入地了解EBV对细胞死亡影响的分子基础不仅丰富了病毒肿瘤学领域,而且还确定了药物开发的靶点。此外,从本综述中收集到的见解可以促进旨在预防EBV感染或减少其致癌影响的疫苗的设计。创新的是,该综述综合了最近发现的非编码rna和细胞信号通路在EBV感染背景下调节细胞死亡的多方面作用。通过巩固现有知识和确定缺乏了解的领域,它为未来的研究奠定了基础,从而可能导致ebv相关癌症的疫苗开发和治疗干预措施取得重大进展。这篇综述强调了对EBV和宿主细胞死亡机制之间复杂的相互作用进行持续研究的关键必要性,最终目标是提高EBV相关疾病患者的预后。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
4.30
自引率
0.00%
发文量
148
审稿时长
56 days
期刊介绍: Cancer Treatment and Research Communications is an international peer-reviewed publication dedicated to providing comprehensive basic, translational, and clinical oncology research. The journal is devoted to articles on detection, diagnosis, prevention, policy, and treatment of cancer and provides a global forum for the nurturing and development of future generations of oncology scientists. Cancer Treatment and Research Communications publishes comprehensive reviews and original studies describing various aspects of basic through clinical research of all tumor types. The journal also accepts clinical studies in oncology, with an emphasis on prospective early phase clinical trials. Specific areas of interest include basic, translational, and clinical research and mechanistic approaches; cancer biology; molecular carcinogenesis; genetics and genomics; stem cell and developmental biology; immunology; molecular and cellular oncology; systems biology; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; cancer policy; and integration of various approaches. Our mission is to be the premier source of relevant information through promoting excellence in research and facilitating the timely translation of that science to health care and clinical practice.
期刊最新文献
Cervical cancer during pregnancy: Management and maternal and perinatal outcomes. Letter to the Editor: Partial nephrectomy vs. percutaneous thermal ablation of small renal masses. Can we define the clinical variables predicting T0 after neoadjuvant systemic therapy in bladder cancer? Towards identification of novel inhibitors of EGFR mutants through in-silico approach. RHOXF1/TSGA10 axis: a possible molecular mechanism of carcinogenesis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1